Tamoxifen Unknown Status Phase 3 Trials for Cancer, Breast Treatment

IndicationsStatusPurposePhase
Unknown StatusTreatment3
clinicaltrials.gov IdentifierTitleDrugs
NCT00010140Epirubicin and Tamoxifen With or Without Docetaxel in Treating Postmenopausal Women With Breast Cancer
NCT00006030Comparison of Four Different Treatment Regimens in Treating Women With Stage I Breast Cancer
NCT00003016Prolonged Tamoxifen Compared With Shorter Tamoxifen in Treating Patients Who Have Breast Cancer
NCT00003418Exemestane Compared With Tamoxifen in Treating Postmenopausal Women With Primary Breast Cancer
NCT00003678Tamoxifen in Treating Women With Breast Cancer
NCT00003680Standard Chemotherapy Compared With High-Dose Chemotherapy Plus Peripheral Stem Cell Transplant in Treating Women With Advanced or Inflammatory Breast Cancer
NCT00003679Combination Chemotherapy in Treating Women With Breast Cancer
NCT00002460Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
NCT01622361Premenopausal Patient With Hormone Responsive, HER2 Negative, Lymph Node Positive Breast Cancer
NCT00629278Combination Chemotherapy and Trastuzumab in Treating Women With Stage I, Stage II, or Stage III HER2-Positive Breast Cancer
NCT00963209Tamoxifen Citrate in Patients With Breast Cancer
NCT00912548Evaluating the Role of the Addition of Ovarian Function Suppression (OFS) to Tamoxifen in Young Women
NCT00893061Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer